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Design of a randomized trial to evaluate the
influence of mobile phone reminders on
adherence to first line antiretroviral treatment in
South India - the HIVIND study protocol
Ayesha De Costa1,2,5*, Anita Shet1,2,5, Nagalingeswaran Kumarasamy3,5, Per Ashorn4,5, Bo Eriksson1,5,
Lennart Bogg1,5, Vinod K Diwan1,5, the HIVIND study team5
Abstract
Background: Poor adherence to antiretroviral treatment has been a public health challenge associated with the
treatment of HIV. Although different adherence-supporting interventions have been reported, their long term
feasibility in low income settings remains uncertain. Thus, there is a need to explore sustainable contextual
adherence aids in such settings, and to test these using rigorous scientific designs. The current ubiquity of mobile
phones in many resource-constrained settings, make it a contextually appropriate and relatively low cost means of
supporting adherence. In India, mobile phones have wide usage and acceptability and are potentially feasible tools
for enhancing adherence to medications. This paper presents the study protocol for a trial, to evaluate the
influence of mobile phone reminders on adherence to first-line antiretroviral treatment in South India.
Methods/Design: 600 treatment naïve patients eligible for first-line treatment as per the national antiretroviral
treatment guidelines will be recruited into the trial at two clinics in South India. Patients will be randomized into
control and intervention arms. The control arm will receive the standard of care; the intervention arm will receive
the standard of care plus mobile phone reminders. Each reminder will take the form of an automated call and a
picture message. Reminders will be delivered once a week, at a time chosen by the patient. Patients will be
followed up for 24 months or till the primary outcome i.e. virological failure, is reached, whichever is earlier.
Self-reported adherence is a secondary outcome. Analysis is by intention-to-treat. A cost-effectiveness study
of the intervention will also be carried out.
Discussion: Stepping up telecommunications technology in resource-limited healthcare settings is a priority of the
World Health Organization. The trial will evaluate if the use of mobile phone reminders can influence adherence to
first-line antiretrovirals in an Indian context.
Trial Registration: Trial registration: ISRCTN79261738.
Background
In the current era of enhanced access to antiretroviral
treatment (ART) globally, the number of people on
ART in low and middle income countries by the end of
2008 has crossed the 4 million mark, with an increase of
1 million from the end of 2007[1]. However, one of the
greatest challenges associated with the management of
HIV is suboptimal adherence to antiretroviral therapy
[2]. Good adherence to ART is beneficial to patients, as
it minimizes treatment failure and prolongs survival. In
addition, it has public health benefits. This is because
poor adherence gives rise to the potential for develop-
ment of drug-resistant strains [3], necessitating adminis-
tration of expensive second-line therapy, and the
possibility of transmission of drug-resistant HIV by non-
adherent patients [4,5].* Correspondence: Ayesha.de.costa@ki.se
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Adherence is known to be influenced by diverse char-
acteristics of individuals, by their environments and by
the treatment regimen prescribed [6]. There have been
some successful interventions targeting patient-related
social and psychological barriers to adherence, including
Directly Administered ART (DAART) and peer support
[7,8]. However, concerns have been raised over the
quantum of healthcare resources that may be required
to implement and sustain such expensive interventions,
particularly in resource-constrained settings [6]. The
Cochrane database of systematic reviews [9], reviewed
studies of patient support and education for promoting
adherence to ART. The 10-year review (1996-2005)
included only studies, which used a randomized con-
trolled trial design to assess the intervention and mea-
sured adherence at a minimum of 6 weeks. Only 19
studies met these inclusion criteria, and none of these
had been conducted in low income settings (12 were in
the US, 5 in Europe and 2 in Australia). Thus there is a
need, particularly in low-income settings, to use sustain-
able contextual adherence aids, and to test these aids,
using rigorous scientific design, at the population level.
There has been recent interest in the potential use of
mobile phone technology for various aspects of health
care, particularly in low-income settings [10-12]. Pre-
sently, 64% of all mobile phone users are in the develop-
ing world [13]. The current ubiquity of the mobile
phone in resource-constrained settings [14], makes
phone contacts a contextually appropriate, relatively
low-cost means of supporting adherence. There have
been few reports on the use of mobile phones in HIV
care, within small cohorts of HIV patients from North
[15]and South America [10], and Africa [16]. There
have, so far, been no reports from randomized trials
evaluating the influence of mobile phone reminders on
adherence to ART; however a Kenyan trial evaluating
this concept is currently ongoing [17].
India, which has over 275,000 patients on first line
ART[18], is well suited to explore the influence of the
mobile phone on adherence to ART, given the wide-
spread connectivity, low costs and growing popularity of
the mobile phone. Between 10 and 12 million connec-
tions are added every month to a base of 471 million
connections [19]. Given that India is scaling up its
national program for access to first-line ART, and that
the use of the mobile phone is so widespread and rela-
tively inexpensive, we plan to test in randomized con-
trolled trial design, a hypothesis that mobile telephone
reminders will influence adherence and hence time to
virological failure in ART naïve, HIV infected patients,
initiated on first-line therapy in South India. This proto-
col describes the methods proposed in the conduct of
the trial.
Methods/Design
This study is a two-centre, parallel group, randomized
controlled trial. Eligible participants are randomized in a
1:1 allocation ratio to one of two arms: an intervention
arm, in which the participants receive reminders via
their mobile phones in addition to the standard of care
(defined below); and a control arm in which they receive
only the standard of care.
Study setting and participants
Patients will be recruited from two institutions located in
the capital cities of two different provinces in South India.
One of these is an infectious disease clinic at a teaching
university hospital in Bangalore, while the other is a com-
prehensive HIV treatment and care center in Chennai.
Both are non-profit organizations with large clinics cater-
ing to both urban and rural populations in South India.
Inclusion criteria
Eligible participants include (i) HIV positive patients, (ii)
between 18-60 years of age, (iii) who are ART naïve
(defined as not having taken ART for more than 14
consecutive days previously),(iv) reside in the South
Indian provinces, (v) and who meet criteria for initiation
of first-line ART as per the national guidelines [20].
Exclusion criteria
Patients who are (i) severely ill (Karnofsky score[21] less
than 70), (ii) those who are unable to participate in all
study visits or (iii) those who reside in an area where
there is no mobile telephone network will not be eligible
to participate in the study. Further, to prevent contami-
nation effects, patients belonging to a household where
another member has already been recruited into the
study, will not be eligible.
Informed consent
All eligible patients will individually be given an initial
verbal description of the proposed study by a research
assistant. Interested individuals will then be presented a
written informed consent form. The form will also be
verbally explained as there likely to be varying levels of
literacy among potential participants. A signature, or
thumb imprint, will be obtained from all those who con-
sent to participate. The written informed consent form
will be in English, Kannada and Tamil, as patients
attending the study clinics speak one or more of these
languages. Consent will be obtained by a trained
research assistant, who is not involved in the routine
clinical care of the patient.
Randomization
Stratified randomization, separately for male and female
participants, will be performed. Within each stratum,
block randomization will be used to ensure balanced
representation in the two treatment arms (control and
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intervention) as recruitment progresses. Blocks of 4 and
6 will be used. Sequentially numbered opaque sealed
envelopes will serve as an allocation concealment
method [22]. Envelopes will be located at the two study
clinics. Once randomized, patients will be assigned to
their respective study arms by a study nurse, and each
will be given a study identification number.
Intervention
The intervention which will be evaluated in this trial will
consist of interactive voice and text messages sent to
patients’ mobile phones as reminders to take their ART.
This intervention will be compared against the standard of
care.
Standard of care
All patients in the study will receive the routine stan-
dard of care, as prescribed by the Indian national ART
guidelines[18]. This will include three counseling ses-
sions prior to initiation of ART, routine clinical and
laboratory tests at baseline, and follow-up assessments
as prescribed in the guidelines.
The intervention was designed following several dis-
cussions with the project team and with non-project
clinical staff, as well as a pilot interview study with
patients routinely attending the clinics [23].
The pilot study revealed that although 75% of patients
owned mobile phones, use of the text messaging func-
tion was low, possibly because of relatively low literacy
rates. Phones were used mostly for conversation. For the
study intervention, an automated interactive voice mes-
sage in the local language was selected, along with neu-
tral pictorial messages instead of text messages, as these
are language-independent and are less likely to lead to
stigma should the phone be shared.
Thus the intervention will consist of 2 parts (i) an a
utomated voice call that will go out once a week to
patients in the intervention arm, at a time decided upon
by each patient. The call will be interactive, as the patient
will respond to a question about whether his or her pill
doses were taken the previous day, by pressing ‘1’ for yes
or ‘2’ for no. If the patient fails to respond to the call, a
maximum of three more calls will be made over the
ensuing 24 hours, until a response is obtained. (ii) A
weekly non interactive neutral pictorial message will be
sent out as a reminder 4 days after automated call.
All participants in the intervention arm will receive an
explanation of the details of the intervention at recruit-
ment. Participants will hear the recorded message that
they will receive as an automated call, and informed of
how to respond to this (clicking the digits 1 or 2 as
appropriate). In addition, participants will also be
trained on how to view messages on their phones and
shown the image that they will receive as a reminder.
Patients in the control arm will also be given a mobile
phone, but no interventions as described above will be
made in this arm. This will be done to obviate any effect
that simply ‘receiving a mobile phone’ might have on
adherence.
Participants will receive the intervention at no added
cost, as receiving calls or text messages are free within
Indian phone networks. All participants (control and
intervention) will be given air time credit of Rs. 100
(US$ 2.5) per month. Participants in both arms can call
the clinic staff via their mobile phones whenever neces-
sary, and a record of these calls will be maintained in a
log book.
Outcome Measures
Primary outcome
The primary outcome will be measured as time (in
weeks) to virological failure which defined as a plasma
viral load of more than 400 copies/ml on each of two
consecutive samples measured one month apart, six
months after initiating ART. The date of the first assess-
ment of a plasma viral load more than 400 copies/ml
will be documented as the date of virological failure.
Virological failure was chosen as a primary outcome, as
this is a biological surrogate marker of poor adherence,
and is an objective measure. For the primary outcome,
patients in each arm will be followed up for 24 months
(after initiating ART) or until virological failure occurs,
whichever is earlier.
Secondary outcome
Participant adherence to ART during the study period of
24 months will be the secondary outcome. At each visit,
adherence is measured using the 4-day recall [24] and
the 30-day visual analogue scale [25]. A pill count is
also done at every follow-up study visit.
Quality Control
Standard operating procedures for key processes in the
study have been developed. Prior to recruitment, the
field team will receive extensive training on the objec-
tives, methods and processes of the study, as well as
on the concept of ethical research. In order to achieve
optimal quality of data from questionnaires and labora-
tory tests, training and random checks by the site
coordinator will be adopted. Completed questionnaires
will be reviewed daily by the site coordinator for com-
pleteness, errors and inconsistencies. Quality assurance
protocols will be set in place to maintain quality of
processes and data collection in the clinic. In addition
data collected will be subject to a second phase of
checking through in built checks in the database
(while entering data) and supervision of data entry by
a trained person.
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Sample size
The primary end point in the trial will be time to virolo-
gical failure as estimated using the standard life-table
technique and illustrated by Kaplan Meier survival
curves [26]. The baseline assumptions in the sample size
calculation, are that the risk for virological failure in the
control arm will be 10% [27] (risk rate 0.1), while the
intervention will reduce this risk to 3% (0.03). The
assumptions for this level of risk in the control arm and
intervention arm are based on a review of available lit-
erature [8,28,29]. Stata 10 sample size software module
was used to determine the necessary sample size for a
comparison of the survival times between the two arms,
using the log rank two-sided test. The significance level
or alpha level was set to 0.05 for a two-tailed test, and
the power (probability to detect a deviation of hazard
ratio from unity) requested was 0.90 (90%). Given this, a
sample size of 266 in each arm (n = 1:1) was deter-
mined. Assuming an attrition rate of 10%, this sample
size was inflated by 10% to compensate for loss to fol-
low-up, which gives a total sample of 292 in each arm.
Thus a total of 600 patients newly initiated on ART will
be recruited, with 300 in each arm of the trial. By hav-
ing 300 participants in each arm, the trial will have suf-
ficient power to detect a clinically significant difference
between the arms. With a planned recruitment rate of
4-8 participants per week at each centre, the recruit-
ments for the study will be completed within approxi-
mately 12 to18 months.
A flow diagram of the study design is presented in
figure 1.
Statistical analysis
The primary aim of the statistical analysis is to compare
the two arms, with respect to the primary and secondary
outcomes, i.e. the time to virological treatment failure
and adherence. In both cases, we plan to estimate the
deviation between the two arms and assess statistical
significance, i.e. the probability that the deviation is due
to random variation. The estimation results will be
given as point estimates and confidence intervals.
Given the primary end point, the conventional
approach for the analysis of risks would be to study the
risk ratio and hazard ratio (RR, HR). In addition, the
study of the risk difference (RD) will provide informa-
tion on the expected number of cases that actually ben-
efit from the intervention in terms of avoided failures.
The risk analysis will be carried out using survival
analysis techniques. Survival curves will be constructed
using the Kaplan-Meier life table technique; these will
then be compared using log- rank tests, possibly strati-
fied. Cox regression models will also be employed. As
the risks of treatment failure are likely to be rather
small, a simplified analysis, using for e.g. Poisson
regression will give very similar results. The observed
time for any patient will be adjusted for periods that
could not be observed due to no-show. Patients with-
drawn for reasons other than virological failure, and
patients lost to follow-up, will be right censored, but
included in the analysis for the periods during which
they could be observed.
With regard to the secondary outcome, the different
adherence variables will be numeric hence other models
and tests are required. The main aims are to study the
average adherence, variation of adherence within as well
as between participants, and trends over time. Increased
adherence might be of limited value if the variation
remains large. Different models for Analysis of Variance
(ANOVA) with provision for repeated measurements
will be used. The distribution of adherence at any point
in time is likely to be negatively skewed. This will neces-
sitate analysis, using distribution-free (non-parametric)
statistical methods, or transformations of original data.
Intention to treat analyses (ITT) will be used for the
comparison of primary and secondary outcomes
between arms. Thus a patient assigned to the interven-
tion arm will be considered as belonging to that arm
even if he or she clearly does not perform according to
the protocol.
Analyses will be carried out using the program
STATA, version 10.
Interim analysis
An independent data safety and monitoring committee,
including a statistician, has been established to perform
an interim analysis. This analysis of the failures occur-
ring in each arm is scheduled to occur when 150
patients have been recruited into each arm. The interim
analysis team will carry out the analysis blinded. The
primary aim of the interim analysis is to assess if the
intervention arm shows a clearly better, or worse, out-
come, in terms of failures, than the control arm. The
result will guide the discussion about whether to con-
tinue or end the trial. The interim analysis will also con-
sider the accumulated reported adverse effects in both
two arms.
Subgroup analyses
In addition to analyses that aim at hypothesis testing, we
will also carry out exploratory analyses that will produce
descriptive data that can be used for subsequent hypoth-
esis generation and to provide additional information
about the effects of the intervention on different partici-
pant sub groups (by age, sex, rural/urban, socioeco-
nomic strata, literacy).
Other sub-studies
The trial will also provide a clinical platform to study
adverse drug reactions to national first-line ART among
newly ART-initiated individuals. Other clinical studies
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Figure 1 Flow Diagram of Study Design.
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will include those on the incidence of opportunistic
infections, on immune reconstitution inflammatory syn-
dromes, and on the influence of ART on changes in
nutritional status and dietary intake, within two years of
initiating ART. In addition, in the intervention arm,
adherence reported over the telephone will be compared
with self reported measures. Qualitative studies explor-
ing the responses and perceptions of intervention arm
participants towards the mobile phone intervention and
the experiences of clinic staff with this modality will be
included.
Economic analysis
A cost-effectiveness analysis of the intervention from a
governmental perspective will be performed. The princi-
ple of marginal costing will be used to cost the
resources utilised in the alternative strategies. Full cost-
ing, by absorption costing or by activity based costing,
would not be relevant for this study, since the purpose
is to provide a basis for rational decision making. In a
decision-making process the fixed costs are irrelevant,
since they will not be affected by the choice of either
alternative strategy. All costs of a historical nature, so-
called sunk costs such as resources invested in buildings,
equipment, and vehicles will be ignored. Only costs
related to the future, from the onset of the study, will
be recorded.
A further restriction is that only differential costs will
be collected, i.e. costs that are different between the two
alternative strategies. Costs that are common to the two
alternative strategies will be ignored. In the case of use
of materials, the replacement cost will be used, i.e. not
the accounting cost or the historical cost of the
resources, but the current cost of replacing the
resources will be applied.
The process of costing will be as follows. First, the
relevant resources will be identified that are differential
for the alternative strategies. Second, the quantities of
resource use will be measured, e g the time spent by dif-
ferent clinic staff on the patient. Third, the cost of the
resource consumption will be calculated, by multiplying
the time or numbers of the resource with a standard
cost of the resource. The historical prices recorded in
the accounts will not be used, since these would result
in measuring differences in price levels rather than dif-
ferences in resource consumption.
Ethical issues
The study protocol has been ethically approved by insti-
tutional ethical review boards in all the participating
and collaborating institutions. The rights and welfare of
the participants will be protected according to the
Declaration of Helsinki Ethical Principles for Medical
Research Involving Human Subjects. Clinical care and
emergency medical services are provided by the partici-
pating institutions. Data that is collected as part of the
study will be not be linked to any individual, personal
identifiers will not be used in data storage, and confi-
dentiality will be maintained at all levels of data
management.
An important consideration in this study design is the
possibility of stigma, as patients may not have disclosed
their HIV status to people they live and work with. It is
conceivable that some stigma may be attached to receiv-
ing a mobile phone from the hospital. Participants in
the intervention arm also run the risk of being stigma-
tized, due to the receipt of regular text and voice mes-
sages. To minimize this risk, the picture messages that
the patients will receive as reminders, will be neutral
pictures, which the patient is shown, and approves at
the enrollment visit. With regard to the automated call,
the patient chooses a particular time based on his sche-
dule, when s/he has the privacy to receive and respond
to the call. Detailed counseling on potential stigma
issues will accompany routine counseling at recruitment
and at subsequent study visits.
Discussion
Methodological
As patients are not blinded to the intervention they
receive, a Hawthorne effect in the intervention arm is a
possibility. This could exaggerate the difference in
adherence between the two arms. Also the attention
given to trial participants at the clinics, in itself may
raise adherence in both arms.
With regard to the intervention, the receipt of auto-
mated calls can be recorded, hence the study team will
know that the call was received and attended to (based
on the response received from the patient). However,
though patients will be trained to look at the sms on
their phone, it is not possible to know if the patient
actually read the sms sent out, or if it remained unread
on his/her phone. Interactive sms alone was not chosen
as a method in this study, given the low usage of the
sms function in this setting [23].
The trial will study the influence of the entire inter-
vention. It will not be able to assess the degree to which
each component of the intervention contributed to any
observable difference.
Telecommunications in healthcare in resource
limited settings
The World Health Organization has indicated that incor-
porating the use of newer technology, such as telecom-
munications, in resource-limited settings to enhance
healthcare delivery, is a priority [30]. Mobile phones offer
promise for use in healthcare, particularly in low income
settings, given the centrality of their use in everyday life.
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Living in resource-poor environments is not a barrier to
the use of mobile phones. There is evidence that the exis-
tence of a so-called “digital divide” along the socio-eco-
nomic gradient is less pronounced when it comes to
mobile phones than with regard to other communication
technologies, such as the Internet [14].
The telecommunications network in India is the third
largest in the world, with a total of 509 million connec-
tions, of which 471 million are mobile telephone con-
nections [31]. The use of mobile phones in the country
has increased rapidly along with falling costs of mobile
telephone services. India has also begun to scale up of
it’s National AIDS control program, providing first-line
ART free of cost. In a pilot study at one of the trial cen-
ters clinic [23], we found that 75% of clinic attendees
owned mobile phones, making this a contextually appro-
priate intervention.
Though studies on the use of telephones in promoting
adherence to ART exist [28,32], they have been carried
in high-income areas of the world, where fixed tele-
phone infrastructure exists. These trials reported no
influence on time to virological failure, but did indicate
a positive impact on self-reported adherence.
Mobile telephones are increasingly relevant in India,
and in many parts of the developing world, as they are
low-cost, easily available and used commonly in every-
day life [33]. The results of this trial are expected to
provide evidence of the influence of mobile phone
reminders on improving adherence to first-line ART in
an Indian context. This intervention is also expected to
delay treatment failure, and hence preserve expensive
second-line ART. As this is the first such trial in India
as well as in Asia, the results will highlight key implica-
tions for other low-income settings globally, where there
is rapid growth in acess to mobile phones, and the
potential for their incorporation into many aspects of
routine healthcare.
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